Maximum Standardized Uptake Value From Staging FDG-PET/CT Does not Predict Treatment Outcome for Early-Stage Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy

Burdick, Michael J.; Stephans, Kevin L.; Reddy, Chandana A.; Djemil, T.; Srinivas, Shyam; Videtic, Gregory M.M.

doi:10.1016/j.ijrobp.2009.09.081

Cited by 85 publications

(70 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In SBRT, the utility of SUV max as a prognostic factor for stage I NSCLC remains unclear; several previous studies have identified no significant association between SUV max and patient outcomes (21)(22). Burdick et al (22) analyzed pretreatment SUV max in 72 patients with inoperable T1-2N0M0 NSCLC treated with SBRT and concluded that pretreatment SUV max did not predict for local control, mediastinal failure, distant metastases or OS.…”

Section: Discussionmentioning

confidence: 99%

“…Burdick et al (22) analyzed pretreatment SUV max in 72 patients with inoperable T1-2N0M0 NSCLC treated with SBRT and concluded that pretreatment SUV max did not predict for local control, mediastinal failure, distant metastases or OS. In Japan, Takeda et al (23) revealed that a high SUV max of the primary tumor was associated with a significantly worse local control rate in 95 patients with NSCLC treated with SBRT.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

et al. 2017

View full text Add to dashboard Cite

Abstract. The present study (University Hospital Medical Information Network study no. UMIN000003797) aimed to evaluate whether the maximum standardized uptake value (SUV max ) of pretreatment 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is prognostic factor for stage I non-small cell lung cancer (NSCLC) treated with carbon ion radiotherapy (C-ion RT). Patients treated between June 2010 and June 2013 at Gunma University Heavy Ion Medical Center (Maebashi, Japan) on a prospective protocol were included in the present study. Patients with T1a-b and T2a NSCLC were treated with C-ion RT at a dose of 52.8 Gy [relative biological effectiveness (RBE)] and 60.0 Gy (RBE), respectively, in four fractions. Prior to treatment, all patients underwent FDG-PET, in which the SUV max of primary tumors was evaluated. Local control, progression-free survival (PFS), and overall survival (OS) were calculated. A total of 45 patients were analyzed and the median follow-up period was 28.9 months. The 2-year local control, PFS and OS rates for all patients were 93, 78 and 89%, respectively. The mean SUV max of primary tumors was 5.5, and patients were divided into higher (≥5.5) and lower (<5.5) SUV max groups. The 2-year PFS rates were 61 and 89% for the higher and lower SUV max groups, respectively (P=0.01), and the 2-year OS rates for the higher and lower SUV max groups were 76 and 96%, respectively (P=0.01). The higher SUV max group exhibited a significantly worse PFS and OS compared with the lower SUV max group; however, the SUV max was not associated with the local control rate. In total, 2 patients (4%) experienced grade 2 or 3 radiation pneumonitis, with their symptoms improved through conservative treatment. No patients experienced any grade 4 or 5 toxicities. The results of the present study indicate that pretreatment SUV max is a prognostic indicator for outcomes in patients with stage I NSCLC treated with C-ion RT.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…To date, no study has evaluated the use of DW-MRI as a predictor for NSCLC treated with SBRT. Several studies have found that PET might be a useful predictor for patients with earlystage NSCLC treated with SBRT, but the results are controversial [12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and 18F-FDG PET

Iizuka¹,

Matsuo²,

Umeoka³

et al. 2014

European Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…The majority of reports describe the role of SUVmax in predicting response to therapy, but its prognostic meaning is still controversial [14]. SUV is a semiquantitative measurement of tracer uptake.…”

Section: Discussionmentioning

confidence: 99%

“…The inclusion of WB PET values in the software system, especially for the evaluation of more common and aggressive cancers (i.e. breast cancer, lung cancer, head and neck cancer, colon-rectal cancer), should be considered, in accordance with most recent evidence [14,17,24,25].…”

Section: Discussionmentioning

confidence: 99%

Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Evangelista

Cervino

Ghiotto

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Maximum Standardized Uptake Value From Staging FDG-PET/CT Does not Predict Treatment Outcome for Early-Stage Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy

Cited by 85 publications

References 30 publications

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and 18F-FDG PET

Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Contact Info

Product

Resources

About